Editorial Quality Improvement
Does tranexamic acid reduce 30-day readmission in rural primary-care patients? A quality-improvement audit

Does tranexamic acid reduce 30-day readmission in rural primary-care patients? A quality-improvement audit

Authors

Omar Patel

Omar Patel

King Fahad Medical City, Chile

Mateo Kowalski

Mateo Kowalski

St Thomas' Hospital, Mauritius

Rania Kaur

Rania Kaur

Royal Melbourne Hospital, Costa Rica

Lina Ahmed

Lina Ahmed

Aga Khan University Hospital, Barbados

Corresponding

Published

January 10, 2024

Paper ID

PAP-000045

Status

Published

DOI

10.65712/tmj.test000303

Does tranexamic acid reduce 30-day readmission in rural primary-care patients? A quality-improvement audit

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: 30-day readmission remains a leading cause of avoidable harm among rural primary-care patients. Methods: Missing data were handled with multiple imputation. Results: 3064 participants were included (median age 40 years). The adjusted odds ratio was 0.79 (95% CI 0.48 to 0.84). Conclusion: These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients.

References

1. Zhang K, Patel G, et al. Machine-learning triage and glycaemic control. Crit Care Med. 2021;355(6):516-1456.

2. Volkov P, Tanaka Y, et al. A sepsis alert system and glycaemic control. N Engl J Med. 2025;77(2):256-1238.

3. Haddad Q, Lindqvist S, et al. Frailty screening and length of stay. BMJ. 2010;63(8):473-1570.

4. Nakamura Q, Larsen Q, et al. An enhanced recovery pathway and falls. Crit Care Med. 2020;205(11):87-1007.

5. Nasser A, Osei L, et al. A sepsis alert system and emergency department revisits. BMC Med. 2011;91(3):799-1297.

6. Schmidt C, Nasser Y, et al. Nurse-led discharge planning and health-related quality of life. BMC Med. 2021;380(9):645-1719.

7. Okafor B, Tanaka L, et al. Delayed cord clamping and in-hospital mortality. Eur Heart J. 2022;216(1):353-1574.

8. Ibrahim G, Moreau F, et al. A sepsis alert system and emergency department revisits. JAMA. 2009;334(6):26-1062.

9. Costa D, Kaur A, et al. Pharmacist-led medication review and surgical site infection. BMC Med. 2024;52(5):252-1675.

Introduction

Earlier studies of tranexamic acid were small or single-centre.

Guidelines make only a weak recommendation on tranexamic acid. 30-day readmission remains a leading cause of avoidable harm among rural primary-care patients. Practice around tranexamic acid varies widely between centres.

Materials and Methods

Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.

Eligible participants were rural primary-care patients. Analyses were adjusted for age, sex and baseline severity.

Results

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.56 (95% CI 0.43 to 0.64).

Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.

GroupnEventsRate %
Intervention2194016.1
Centre B26252.1
Female3762326.5
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Kaplan–Meier curve for 30-day readmission
Shown for rural primary-care patients; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Kaplan–Meier curve for 30-day readmission
Shown for rural primary-care patients; error bars are 95% confidence intervals.

Serious adverse events were rare and similar between groups. 3026 participants were included (median age 32 years). 30-day readmission occurred in 19% of the intervention group versus 34% of controls.

2978 participants were included (median age 60 years). Effects were consistent across prespecified subgroups.

Discussion

Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients.

Strengths include the sample size and blinded outcome assessment.

Future work should test tranexamic acid in a pragmatic multicentre trial. These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients. Implementation will depend on staffing, cost and local protocols.

Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.

Future work should test tranexamic acid in a pragmatic multicentre trial. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment. These findings suggest that tranexamic acid is associated with better 30-day readmission in rural primary-care patients.

Conclusions

Tranexamic acid merits wider use for rural primary-care patients to improve 30-day readmission.

Appendices

Ethics approval: IRB-6689.